Shots:

• Novartis- Amgen and Banner Alzheimer's Institute discontinue two P-II/III studies evaluating the safety & efficacy of CNP520 for the prevention or the delay of the onset of Alzheimer's disease due to lack of efficacy and worsening of cognitive function in the patients
• In Aug’2015- Amgen & Novartis collaborated to develop & commercialize therapies for migraine & Alzheimer's disease- sponsored by both the companies in collaboration with Banner Alzheimer's Institute
• CNP520 (PO) is a BACE (aspartyl protease) inhibitor designed to reduce Aβ production to prevent or treat Alzheimer's disease

Click here to read full press release/ article | Ref: Novartis | Image: Novartis